Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

PDL BioPharma Inc (NASDAQ:PDLI)

3.34
Delayed Data
As of May 27
 +0.08 / +2.45%
Today’s Change
2.58
Today|||52-Week Range
6.83
-5.65%
Year-to-Date
PDLI Regular Dividend: PDLI will begin trading ex-dividend on 06/02/16 with a $0.05 dividend payable to shareholders of record as of 06/06/16.
3 Small Biotechs That Look Very Healthy
May 27 / TheStreet.com - Paid Partner Content
PDL BioPharma Agrees to Equity Investment in Noden Pharma
May 25 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close3.26
Today’s open3.26
Day’s range3.22 - 3.37
Volume1,141,442
Average volume (3 months)2,103,978
Market cap$528.4M
Dividend yield5.99%
Data as of 4:00pm ET, 05/27/2016

Growth & Valuation

Earnings growth (last year)+9.14%
Earnings growth (this year)-77.92%
Earnings growth (next 5 years)+17.00%
Revenue growth (last year)+0.66%
P/E ratio1.8
Price/Sales0.99
Price/Book0.76

Competitors

 Today’s
change
Today’s
% change
XNCRXencor Inc+0.28+2.07%
SCMPSucampo Pharmaceutic...+0.67+5.70%
SPPISpectrum Pharmaceuti...-0.01-0.13%
RVNCRevance Therapeutics...+0.25+1.28%
Data as of 4:00pm ET, 05/27/2016

Financials

Next reporting dateJuly 27, 2016
EPS forecast (this quarter)$0.08
Annual revenue (last year)$585.1M
Annual profit (last year)$332.8M
Net profit margin56.88%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
John Peter McLaughlin
Chief Financial Officer &
Vice President
Peter S. Garcia
Corporate headquarters
Incline Village, Nevada

Forecasts

Partner Offers

Search for Jobs